Following improvement of the efficacy and specificity of PLTFBH analogs to DNAJA1 and evaluation of their pharmacological properties, it is crucial to test their in vivo effects on tumor progression, as well as toxicity and safety, using pre-clinical studies. Here, DNAJA1 is linked to neoplasm.